Gene delivery for immunoengineering

Neshat, Sarah Y.; Tzeng, Stephany Y.; Green, Jordan J.

doi:10.1016/j.copbio.2020.05.008

Cited by 29 publications

(20 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The knowledge accumulated from these results will be used to design better treatments for various biomedical applications. These include, but are not limited to, designing better synthetic and biomaterials for delivering immunomodulatory drugs or biologics [ 1 ], increasing drug and gene delivery efficiency in target immune cells [ 2 ], and enhancing immune cell behavior with nanomaterials [ 3 ]. Being that this is a new field that is rapidly expanding, with growing interest in public institutions, private sectors and funding bodies, the translational impact of nano-immunoengineering is expected to increase even more in the next decade [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications

et al. 2022

View full text Add to dashboard Cite

Immunotherapy has reached clinical success in the last decade, with the emergence of new and effective treatments such as checkpoint blockade therapy and CAR T-cell therapy that have drastically improved patient outcomes. Still, these therapies can be improved to limit off-target effects, mitigate systemic toxicities, and increase overall efficacies. Nanoscale engineering offers strategies that enable researchers to attain these goals through the manipulation of immune cell functions, such as enhancing immunity against cancers and pathogens, controlling the site of immune response, and promoting tolerance via the delivery of small molecule drugs or biologics. By tuning the properties of the nanomaterials, such as size, shape, charge, and surface chemistry, different types of immune cells can be targeted and engineered, such as dendritic cells for immunization, or T cells for promoting adaptive immunity. Researchers have come to better understand the critical role the immune system plays in the progression of pathologies besides cancer, and developing nanoengineering approaches that seek to harness the potential of immune cell activities can lead to favorable outcomes for the treatment of injuries and diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications

et al. 2022

View full text Add to dashboard Cite

show abstract

“… 26 , 27 Despite their high transformation efficiency, the biocompatibility and safety of viral vectors remain controversial. 21 , 26 , 28 In addition, the immunogenicity of liposomes, the poor delivery efficiency of peptides, and the cytotoxicity of cationic polymers still require further studies to determine whether these materials are suitable as gene delivery vectors. 20 , 29 , 30 Among the inorganic nanoparticles, mesoporous silica nanoparticles (MSNs) exhibit excellent potentials as drug and gene delivery vectors due to their favorable biocompatibility, chemical stability, large surface area, and simple synthesis process.…”

Section: Introductionmentioning

confidence: 99%

Antisense vicR-Loaded Dendritic Mesoporous Silica Nanoparticles Regulate the Biofilm Organization and Cariogenicity of Streptococcus mutans

Tian

Zhang

et al. 2022

IJN

View full text Add to dashboard Cite

“… 12 , 13 , 14 , 15 Recently, multiple gene delivery vectors have been developed in the expanding field of cancer immunotherapy. 16 Cancer immunotherapy approaches modulate the activity of immune cells against cancer cells in various ways, e.g., by rendering the immunosuppressive state of the tumor microenvironment (e.g., by blocking the PD-1/PD-L1 axis) or by stimulating immune cell activation (e.g., by cytokine interleukin [IL]-12 or IL-2 release) to eradicate cancer cells. 17 …”

Section: Introductionmentioning

confidence: 99%

iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy

Brücher

Kirchhammer

Smith

et al. 2021

Molecular Therapy - Methods & Clinical Development

View full text Add to dashboard Cite

Adenovirus-mediated combination gene therapies have shown promising results in vaccination or treating malignant and genetic diseases. Nevertheless, an efficient system for the rapid assembly and incorporation of therapeutic genes into high-capacity adenoviral vectors (HCAdVs) is still missing. In this study, we developed the iMATCH (integrated modular assembly for therapeutic combination HCAdVs) platform, which enables the generation and production of HCAdVs encoding therapeutic combinations in high quantity and purity within 3 weeks. Our modular cloning system facilitates the efficient combination of up to four expression cassettes and the rapid integration into HCAdV genomes with defined sizes. Helper viruses (HVs) and purification protocols were optimized to produce HCAdVs with distinct capsid modifications and unprecedented purity (0.1 ppm HVs). The constitution of HCAdVs, with adapters for targeting and a shield of trimerized single-chain variable fragment (scFv) for reduced liver clearance, mediated cell- and organ-specific targeting of HCAdVs. As proof of concept, we show that a single HCAdV encoding an anti PD-1 antibody, interleukin (IL)-12, and IL-2 produced all proteins, and it led to tumor regression and prolonged survival in tumor models, comparable to a mixture of single payload HCAdVs in vitro and in vivo . Therefore, the iMATCH system provides a versatile platform for the generation of high-capacity gene therapy vectors with a high potential for clinical development.

show abstract

Gene delivery for immunoengineering

Cited by 29 publications

References 51 publications

Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications

Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications

Antisense vicR-Loaded Dendritic Mesoporous Silica Nanoparticles Regulate the Biofilm Organization and Cariogenicity of Streptococcus mutans

iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy

Contact Info

Product

Resources

About